Active, not recruitingPhase 2NCT05354557

Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Studying Multiple myeloma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Gunjan Shaw, MD, PA-C
Memorial Sloan Kettering Cancer Center
Intervention
Iberdomide(drug)
Enrollment
16 target
Eligibility
18-75 years · All sexes
Timeline
2022 – 2026

Study locations (8)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05354557 on ClinicalTrials.gov

Other trials for Multiple myeloma

Additional recruiting or active studies for the same condition.

See all trials for Multiple myeloma →

← Back to all trials